Solutions from iVexSol are revolutionizing the production of LVVs, which are gene delivery vehicles that are a critical raw material in the manufacture of life-changing cell and gene therapies (CGTs). The technology platform employs banks of vector-producing cells to produce LVV in significantly greater quantities than current approaches while allowing for the rapid scale-out required for global demand, all within a smaller manufacturing footprint. These advancements allow for shorter clinical development timelines, lower costs, and, ultimately, greater global access for patients who are waiting for these transformative medicines.